Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial

Larry A. Weinrauch, John A. D'Elia, Matthew R. Weir, Suphamai Bunnapradist, Peter V. Finn, Jiankang Liu, Brian Claggett, Anthony P. Monaco
  • The American Journal of Medicine, February 2018, Elsevier
  • DOI: 10.1016/j.amjmed.2017.08.038

Anti-rejection and immune therapy are associated with risk of death from infection and malignancy

What is it about?

Immune therapy is being advertised for many different medical problems and prescribed by neurologists, nephrologists, dermatologists, hematologists, gastroenterologists. Successful transplant recipients have been evaluated for heart disease prior to undergoing transplant. In a study designed to determine whether the risk for cardiovascular disease could be reduced by certain vitamins (B12 and folic acid), we observed that the majority of deaths

Why is it important?

As immune therapies increase for various disease, we must be aware of the greater risk on infection and malignancy than cardiovascular disease in populations presumed to be at low risk for heart attack and stroke. Screening for malignancy and attention to vaccination in patients under immune therapy needs to be stressed.

Perspectives

Larry Weinrauch
Harvard Medical School

As immune therapies increase for various disease, we must be aware of the greater risk on infection and malignancy than cardiovascular disease in populations presumed to be at low risk for heart attack and stroke. Screening for malignancy and attention to vaccination in patients under immune therapy needs to be stressed. It would be helpful if databases were analyzed for other information collected that were not necessarily used for the hypothesis that was being tested.

Read Publication

http://dx.doi.org/10.1016/j.amjmed.2017.08.038

The following have contributed to this page: Larry Weinrauch